Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation.

IF 7.4 1区 医学 Q1 HEMATOLOGY Blood advances Pub Date : 2024-10-08 DOI:10.1182/bloodadvances.2024012979
Yaqiu Sang, Robert H Lee, Annie Luong, Éva Katona, Claire S Whyte, Nicholas L Smith, Alan E Mast, Matthew J Flick, Nicola J Mutch, Wolfgang Bergmeier, Alisa S Wolberg
{"title":"Activated platelets retain and protect most of their factor XIII-A cargo from proteolytic activation and degradation.","authors":"Yaqiu Sang, Robert H Lee, Annie Luong, Éva Katona, Claire S Whyte, Nicholas L Smith, Alan E Mast, Matthew J Flick, Nicola J Mutch, Wolfgang Bergmeier, Alisa S Wolberg","doi":"10.1182/bloodadvances.2024012979","DOIUrl":null,"url":null,"abstract":"<p><strong>Abstract: </strong>Platelet factor XIII-A (FXIII-A) is a major cytoplasmic protein (∼3% of total), representing ∼50% of total circulating FXIII. However, mobilization of FXIII-A during platelet activation is not well defined. To determine mechanisms mediating the retention vs release of platelet FXIII-A, platelets from healthy humans and mice (F13a1-/-, Fga-/-, Plg-/-, Stim1fl/flPf4-Cre, and respective controls) were stimulated with thrombin, convulxin plus thrombin, or calcium ionophore (A23187), in the absence or presence of inhibitors of transglutaminase activity, messenger RNA (mRNA) translation, microtubule rearrangement, calpain, and Rho GTPase. Platelet releasates and pellets were separated by (ultra)centrifugation. FXIII-A was detected by immunoblotting and immunofluorescence microscopy. Even after strong dual agonist (convulxin plus thrombin) stimulation of human platelets, >80% platelet FXIII-A remained associated with the platelet pellet. In contrast, essentially all tissue factor pathway inhibitor, another cytoplasmic protein in platelets, was released to the supernatant. Pellet-associated FXIII-A was not due to de novo synthesis via platelet F13A1 mRNA. The proportion of platelet FXIII-A retained by vs released from activated platelets was partly dependent on STIM1 signaling, microtubule rearrangement, calpain, and RhoA activation but did not depend on the presence of fibrinogen or plasminogen. Immunofluorescence microscopy confirmed the presence of considerable FXIII-A within the activated platelets. Although released FXIII-A was cleaved to FXIII-A∗ and could be degraded by plasmin, platelet-associated FXIII-A remained uncleaved. Retention of substantial platelet-derived FXIII-A by activated platelets and its reduced susceptibility to thrombin- and plasmin-mediated proteolysis suggest platelet FXIII-A is a protected pool with biological role(s) that differs from plasma FXIII.</p>","PeriodicalId":9228,"journal":{"name":"Blood advances","volume":null,"pages":null},"PeriodicalIF":7.4000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11459904/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood advances","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1182/bloodadvances.2024012979","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Abstract: Platelet factor XIII-A (FXIII-A) is a major cytoplasmic protein (∼3% of total), representing ∼50% of total circulating FXIII. However, mobilization of FXIII-A during platelet activation is not well defined. To determine mechanisms mediating the retention vs release of platelet FXIII-A, platelets from healthy humans and mice (F13a1-/-, Fga-/-, Plg-/-, Stim1fl/flPf4-Cre, and respective controls) were stimulated with thrombin, convulxin plus thrombin, or calcium ionophore (A23187), in the absence or presence of inhibitors of transglutaminase activity, messenger RNA (mRNA) translation, microtubule rearrangement, calpain, and Rho GTPase. Platelet releasates and pellets were separated by (ultra)centrifugation. FXIII-A was detected by immunoblotting and immunofluorescence microscopy. Even after strong dual agonist (convulxin plus thrombin) stimulation of human platelets, >80% platelet FXIII-A remained associated with the platelet pellet. In contrast, essentially all tissue factor pathway inhibitor, another cytoplasmic protein in platelets, was released to the supernatant. Pellet-associated FXIII-A was not due to de novo synthesis via platelet F13A1 mRNA. The proportion of platelet FXIII-A retained by vs released from activated platelets was partly dependent on STIM1 signaling, microtubule rearrangement, calpain, and RhoA activation but did not depend on the presence of fibrinogen or plasminogen. Immunofluorescence microscopy confirmed the presence of considerable FXIII-A within the activated platelets. Although released FXIII-A was cleaved to FXIII-A∗ and could be degraded by plasmin, platelet-associated FXIII-A remained uncleaved. Retention of substantial platelet-derived FXIII-A by activated platelets and its reduced susceptibility to thrombin- and plasmin-mediated proteolysis suggest platelet FXIII-A is a protected pool with biological role(s) that differs from plasma FXIII.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
活化的血小板会保留并保护其大部分 XIII-A 因子,使其不被蛋白水解活化和降解。
血小板因子(F)XIII-A 是一种主要的细胞质蛋白(约占总量的 3%),约占循环 FXIII 总量的 50%。然而,FXIII-A 在血小板活化过程中的动员机制尚未明确。为了确定介导血小板 FXIII-A 保留和释放的机制,在没有或有转谷氨酰胺酶活性、mRNA 翻译、微管重排、钙蛋白酶和 Rho GTPase 抑制剂的情况下,用凝血酶、纤溶酶+凝血酶或钙离子诱导剂(A23187)刺激健康人和小鼠(F13a1-/-、Fga-/-、Plg-/-、Stim1fl/fl、Pf4-Cre 和各自的对照组)的血小板。通过(超)离心分离血小板释放物和颗粒。通过免疫印迹和免疫荧光显微镜检测 FXIII-A。即使在人体血小板受到强烈的双重激动剂(卷曲霉素+凝血酶原)刺激后,仍有超过 80% 的血小板 FXIII-A 与血小板颗粒相关联。与此相反,血小板中的另一种细胞质蛋白--组织因子通路抑制因子基本上全部释放到上清液中。与血小板结合的 FXIII-A 不是通过血小板 F13A1 mRNA 从新合成的。活化血小板保留和释放的血小板 FXIII-A 的比例部分取决于 STIM1 信号传导、微管重排、钙蛋白酶和 RhoA 激活,但不取决于纤维蛋白原或纤溶酶原的存在。免疫荧光显微镜证实,在活化的血小板中存在大量的 FXIII-A。释放的 FXIII-A 被裂解为 FXIII-A*,并可被血浆蛋白酶降解,而血小板结合的 FXIII-A 仍未被裂解。活化血小板保留了大量血小板衍生的 FXIII-A,而且其对凝血酶和血浆蛋白酶介导的蛋白水解的敏感性降低,这表明血小板 FXIII-A 是一个受保护的池,其生物学作用不同于血浆 FXIII。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Blood advances
Blood advances Medicine-Hematology
CiteScore
12.70
自引率
2.70%
发文量
840
期刊介绍: Blood Advances, a semimonthly medical journal published by the American Society of Hematology, marks the first addition to the Blood family in 70 years. This peer-reviewed, online-only, open-access journal was launched under the leadership of founding editor-in-chief Robert Negrin, MD, from Stanford University Medical Center in Stanford, CA, with its inaugural issue released on November 29, 2016. Blood Advances serves as an international platform for original articles detailing basic laboratory, translational, and clinical investigations in hematology. The journal comprehensively covers all aspects of hematology, including disorders of leukocytes (both benign and malignant), erythrocytes, platelets, hemostatic mechanisms, vascular biology, immunology, and hematologic oncology. Each article undergoes a rigorous peer-review process, with selection based on the originality of the findings, the high quality of the work presented, and the clarity of the presentation.
期刊最新文献
Selective Btk inhibition by PRN1008/PRN473 blocks human CLEC-2, and PRN473 reduces venous thrombosis formation in mice. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma. Cardiac events after allo-HCT in patients with acute myeloid leukemia. Consensus recommendations for severe aplastic anemia. Genetic variants in canonical Wnt signaling pathway associated with pediatric immune thrombocytopenia.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1